ORAI3 and pachyonychia congenita: Considering that Orai3 expression is inversely associated with the PC patients’ survival time and it is overexpressed in a certain proportion of pancreatic tumors, Orai3 appears to be an attractive therapeutic target, at least in the cases where its expression is elevated.